MAP Pharmaceuticals <MAPP.O> said it plans to suspend development of its experimental paediatric asthma drug, after its licensing partner AstraZeneca <AZN.L> terminated a collaboration on the drug.

AstraZeneca CEO Pascal Soriot summarizes his accomplishments at the U.K.-based pharma giant in two words--Lynparza and Tagrisso. | AstraZeneca CEO Pascal Soriot summarizes his accomplishments at ...